Advances in the development of kinase inhibitor therapeutics for alzheimer's disease

Drug Development Research

Volumn 70, Issue 2, 2009, Pages 125-144

  Savage, Mary J ^a   Gingrich, Diane E ^b  

^a MERCK RESEARCH LABORATORIES   (United States)

^b CEPHALON INC   (United States)

Author keywords

Alzheimer; C Jun N terminal kinase; Casein kinase 1; CDK5; CK1; Cyclin dependent kinase 5; Glycogen synthase kinase 3; GSK3; JNK; P21 activating kinase; P38 kinase; Pak; Rho kinase; Rock; Tau

Indexed keywords

2 (2,4 DICHLOROPHENYL) 3 (1 METHYL 3 INDOLYL)MALEIMIDE; 4 (1 AMINOETHYL) N (4 PYRIDYL)CYCLOHEXANECARBOXAMIDE; 4 (4 FLUOROPHENYL) 2 (4 HYDROXYPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ALOISINE; AMYLOID BETA PROTEIN; AR A014418; BA 210; BISINDOLYLMALEIMIDE; CEP 11004; CEP 1347; CKI 7; CP 668863; CP 681301; D 4476; DASATINIB; DORAMAPIMOD; ERLOTINIB; FLAVOPIRIDOL; HYMENIALDISINE; IC 261; IMATINIB; INDIRUBIN; LAPATINIB; LITHIUM CHLORIDE; MALEIMIDE DERIVATIVE; NILOTINIB; NP 12; OLOMOUCINE; PAULLONE DERIVATIVE; PHOSPHOTRANSFERASE INHIBITOR; RAPAMYCIN; ROSCOVITINE; RP 106; SEMAPIMOD; SORAFENIB; SUNITINIB; TAU PROTEIN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ALZHEIMER DISEASE; ARTICLE; CLINICAL TRIAL; DEGENERATIVE DISEASE; DISEASE SEVERITY; DRUG EFFICACY; DRUG INDICATION; DRUG POTENCY; DRUG SELECTIVITY; DRUG TARGETING; HUMAN; MICROGLIA; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PATHOGENESIS; TREATMENT RESPONSE;

EID: 64349085390     PISSN: 02724391     EISSN: 10982299     Source Type: Journal    
DOI: 10.1002/ddr.20287     Document Type: Article

References (221)

1. Aghdam SY, Barger SW. 2007. Glycogen synthase kinase-3 in neurodegeneration and neuroprotection: lessons from lithium. Curr Alzheimer Res 4:21-31.
2. Ahlijanian MK, Barrezueta NX, Williams RD, Jakowski A, Kowsz KP, McCarthy S, Coskran T, Carlo A, Seymour PA, Burkhardt JE, Nelson RB, McNeish JD. 2000. Hyperpho-sphorylated tau and neurofilament and cytoskeletal disruptions in mice overexpressing human p25, an activator of cdk5. Proc Natl Acad Sci USA 97:2910-2915.
3. Alvarez A, Toro R, Caceres A, Maccioni RB. 1999. Inhibition of tau phosphorylating protein kinase cdk5 prevents beta-amyloid- induced neuronal death. FEBS Lett 459:421-426.
4. Askanas V, Engel WK. 2007. Inclusion-body myositis, a multi- factorial muscle disease associated with aging: current concepts of pathogenesis. Curr Opin Rheumatol 19:550-559.
5. Augustinack JC, Schneider A, Mandelkow EM, Hyman BT. 2002. Specific tau phosphorylation sites correlate with severity of neuronal cytopathology in Alzheimer's disease. Acta Neuropathol 103:26-35.
6. Bacher M, Dodel R, Aljabari B, Keyvani K, Marambaud P, Kayed R, Glabe C, Goertz N, Hoppmann A, Sachser N, Klotsche J, Schnell S, Lewejohann L, Al-Abed Y. 2008. CNI-1493 inhibits Abeta production, plaque formation, and cognitive deterioration in an animal model of Alzheimer's disease. J Exp Med 205:1593-1599.
7. Bain J, Plater L, Elliott M, Shpiro N, Hastie CJ, McLauchlan H, Klevernic I, Arthur JS, Alessi DR, Cohen P. 2007. The selectivity of protein kinase inhibitors: a further update. Biochem J 408:297-315.
8. Bandyopadhyay S, Goldstein LE, Lahiri DK, Rogers JT. 2007. Role of the APP non-amyloidogenic signaling pathway and targeting alpha-secretase as an alternative drug target for treatment of Alzheimer's disease. Curr Med Chem 14:2848-2864.
9. Bellucci A, Rosi MC, Grossi C, Fiorentini A, Luccarini I, Casamenti F. 2007. Abnormal processing of tau in the brain of aged TgCRND8 mice. Neurobiol Dis 27:328-338.
10. Berthet C, Aleem E, Coppola V, Tessarollo L, Kaldis P. 2003. Cdk2 knockout mice are viable. Curr Biol 13:1775-1785.
11. Bhat RV, Budd SL. 2002. GSK3beta signalling: casting a wide net in Alzheimer's disease. Neurosignals 11:251-261.
12. Bhat R, Xue Y, Berg S, Hellberg S, Ormo M, Nilsson Y, Radesater AC, Jerning E, Markgren PO, Borgegard T, Nylof M, Gimenez-Cassina A, Hernandez F, Lucas JJ, Diaz-Nido J, Avila J. 2003. Structural insights and biological effects of glycogen synthase kinase 3-specific inhibitor AR-A014418. J Biol Chem 278:45937-45945.
13. Bibb JA, Snyder GL, Nishi A, Yan Z, Meijer L, Fienberg AA, Tsai LH, Kwon YT, Girault JA, Czernik AJ, Huganir RL, Hemmings HC Jr, Nairn AC, Greengard P. 1999. Phosphorylation of DARPP-32 by Cdk5 modulates dopamine signalling in neurons. Nature 402:669-671.
14. Bozyczko-Coyne D, O'Kane TM, Wu ZL, Dobrzanski P, Murthy S, Vaught JL, Scott RW. 2001. CEP-1347/KT-7515, an inhibitor of SAPK/JNK pathway activation, promotes survival and blocks multiple events associated with Abeta-induced cortical neuron apoptosis. J Neurochem 77:849-863.
15. Brandeis M, Rosewell I, Carrington M, Crompton T, Jacobs MA, Kirk J, Gannon J, Hunt T. 1998. Cyclin B2-null mice develop normally and are fertile whereas cyclin B1-null mice die in utero. Proc Natl Acad Sci USA 95:4344-4349.
16. Bu B, Li J, Davies P, Vincent I. 2002. Deregulation of cdk5, hyperphosphorylation, and cytoskeletal pathology in the Niemann-Pick type C murine model. J Neurosci 22:6515-6525.
17. Busciglio J, Lorenzo A, Yeh J, Yankner BA. 1995. beta-amyloid fibrils induce tau phosphorylation and loss of microtubule binding. Neuron 14:879-888.
18. Buxbaum JD, Gandy SE, Cicchetti P, Ehrlich ME, Czernik AJ, Fracasso RP, Ramabhadran TV, Unterbeck AJ, Greengard P. 1990. Processing of Alzheimer beta/A4 amyloid precursor protein: modulation by agents that regulate protein phosphorylation. Proc Natl Acad Sci USA 87:6003-6006.
19. Castro A, Encinas A, Gil C, Brase S, Porcal W, Perez C, Moreno FJ, Martinez A. 2008. Non-ATP competitive glycogen synthase kinase 3beta (GSK-3beta) inhibitors: study of structural requirements for thiadiazolidinone derivatives. Bioorg Med Chem 16:495-510.
20. Chang L, Jones Y, Ellisman MH, Goldstein LS, Karin M. 2003. JNK1 is required for maintenance of neuronal microtubules and controls phosphorylation of microtubule-associated proteins. Dev Cell 4:521-533.
21. Chauhan A, Chauhan VP, Murakami N, Brockerhoff H, Wisniewski HM. 1993. Amyloid beta-protein stimulates casein kinase I and casein kinase II activities. Brain Res 629:47-52.
22. Cho JH, Johnson GV 2003. Glycogen synthase kinase 3beta phosphorylates tau at both primed and unprimed sites. Differential impact on microtubule binding. J Biol Chem 278:187-193.
23. Cho JH, Johnson GV 2004. Glycogen synthase kinase 3 beta induces caspase-cleaved tau aggregation in situ. J Biol Chem 279: 54716-54723.
24. Cohen P. 2002. Protein kinases-the major drug targets of the twenty-first century? Nat Rev Drug Discov 1:309-315.
25. Cordle A, Koenigsknecht-Talboo J, Wilkinson B, Limpert A, Landreth G. 2005. Mechanisms of statin-mediated inhibition of small G-protein function. J Biol Chem 280:34202-34209.
26. Crespo A, Zhang X, Fernandez A. 2008. Redesigning kinase inhibitors to enhance specificity. J Med Chem 51:4890-4898.
27. Cruz JC, Tseng HC, Goldman JA, Shih H, Tsai LH. 2003. Aberrant Cdk5 activation by p25 triggers pathological events leading to neurodegeneration and neurofibrillary tangles. Neuron 40:471-483.
28. Cruz JC, Kim D, Moy LY, Dobbin MM, Sun X, Bronson RT, Tsai LH. 2006. p25/cyclin-dependent kinase 5 induces production and intraneuronal accumulation of amyloid beta in vivo. J Neurosci 26:10536-10541.
29. Cuenda A, Rousseau S. 2007. p38 MAP-kinases pathway regulation, function and role in human diseases. Biochim Biophys Acta 1773:1358-1375.
30. Culbert AA, Skaper SD, Howlett DR, Evans NA, Facci L, Soden PE, Seymour ZM, Guillot F, Gaestel M, Richardson JC. 2006. MAPK-activated protein kinase 2 deficiency in microglia inhibits pro-inflammatory mediator release and resultant neurotoxicity. Relevance to neuroinflammation in a transgenic mouse model of Alzheimer disease. J Biol Chem 281:23658-23667.
31. Dajani R, Fraser E, Roe SM, Young N, Good V, Dale TC, Pearl LH. 2001. Crystal structure of glycogen synthase kinase 3 beta: structural basis for phosphate-primed substrate specificity and autoinhibition. Cell 105:721-732.
32. Dickey CA, Eriksen J, Kamal A, Burrows F, Kasibhatla S, Eckman CB, Hutton M, Petrucelli L. 2005. Development of a high throughput drug screening assay for the detection of changes in tau levels-proof of concept with HSP90 inhibitors. Curr Alzheimer Res 2:231-238.
33. Ebneth A, Godemann R, Stamer K, Illenberger S, Trinczek B, Mandelkow E. 1998. Overexpression of tau protein inhibits kinesin-dependent trafficking of vesicles, mitochondria, and endoplasmic reticulum: implications for Alzheimer's disease. J Cell Biol 143:777-794.
34. Embi N, Rylatt DB, Cohen P. 1980. Glycogen synthase kinase-3 from rabbit skeletal muscle. Separation from cyclic-AMP- dependent protein kinase and phosphorylase kinase. Eur J Biochem 107:519-527.
35. Engler TA, Henry JR, Malhotra S, Cunningham B, Furness K, Brozinick J, Burkholder TP, Clay MP, Clayton J, Diefenbacher C, et al. 2004. Substituted 3-imidazo[1,2-a]pyridin-3-yl-4-(1,2,3,4- tetrahydro-[1,4]diazepino-[6, 7,1-hi]indol-7-yl)pyrrole-2,5-diones as highly selective and potent inhibitors of glycogen synthase kinase-3. J Med Chem 47:3934-3937.
36. Engler TA, Malhotra S, Burkholder TP, Henry JR, Mendel D, Porter WJ, Furness K, Diefenbacher C, Marquart A, Reel JK, et al. 2005. The development of potent and selective bisarylma-leimide GSK3 inhibitors. Bioorg Med Chem Lett 15:899-903.
37. Fagan T. 2008. Flurizan fails final hurdle, company discontinues drug. Alz Res Forum http://wwwalzforum.org/new/detail.asp?id = 1871.
38. Feijoo C, Campbell DG, Jakes R, Goedert M, Cuenda A. 2005. Evidence that phosphorylation of the microtubule-associated protein Tau by SAPK4/p38delta at Thr50 promotes microtubule assembly. J Cell Sci 118(Pt 2):397-408.
39. Ferreira A, Lu Q, Orecchio L, Kosik KS. 1997. Selective phosphorylation of adult tau isoforms in mature hippocampal neurons exposed to fibrillar A beta. Mol Cell Neurosci 9:220-234.
40. Ferrer I, Blanco R, Carmona M, Ribera R, Goutan E, Puig B, Rey MJ, Cardozo A, Vinals F, Ribalta T. 2001. Phosphorylated map kinase (ERK1, ERK2) expression is associated with early tau deposition in neurones and glial cells, but not with increased nuclear DNA vulnerability and cell death, in Alzheimer disease, Pick's disease, progressive supranuclear palsy and corticobasal degeneration. Brain Pathol 11:144-158.
41. Feyt C, Kienlen-Campard P, Leroy K, N'Kuli F, Courtoy PJ, Brion JP, Octave JN. 2005. Lithium chloride increases the production of amyloid-beta peptide independently from its inhibition of glycogen synthase kinase 3. J Biol Chem 280:33220-33227.
42. Fischer PM, Gianella-Borradori A. 2005. Recent progress in the discovery and development of cyclin-dependent kinase inhibitors. Expert Opin Invest Drugs 14:457-477.
43. Flajolet M, He G, Heiman M, Lin A, Nairn AC, Greengard P. 2007. Regulation of Alzheimer's disease amyloid-beta formation by casein kinase I. Proc Natl Acad Sci USA 104:4159-4164.
44. Foltz IN, Lee JC, Young PR, Schrader JW. 1997. Hemopoietic growth factors with the exception of interleukin-4 activate the p38 mitogen- activated protein kinase pathway. J Biol Chem 272:3296-3301.
45. Forman MS. 2004. Genotype-phenotype correlations in FTDP-17: does form follow function? Exp Neurol 187:229-234.
46. Ghoshal N, Smiley JF, DeMaggio AJ, Hoekstra MF, Cochran EJ, Binder LI, Kuret J. 1999. A new molecular link between the fibrillar and granulovacuolar lesions of Alzheimer's disease. Am J Pathol 155:1163-1172.
47. Gilmore EC, Ohshima T, Goffinet AM, Kulkarni AB, Herrup K. 1998. Cyclin-dependent kinase 5-deficient mice demonstrate novel developmental arrest in cerebral cortex. J Neurosci 18:6370-6377.
48. Glicksman MA, Cuny GD, Liu M, Dobson B, Auerbach K, Stein RL, Kosik KS. 2007. New approaches to the discovery of cdk5 inhibitors. Curr Alzheimer Res 4:547-549.
49. Goedert M, Hasegawa M, Jakes R, Lawler S, Cuenda A, Cohen P. 1997. Phosphorylation of microtubule-associated protein tau by stress-activated protein kinases. FEBS Lett 409:57-62.
50. Goldstein D, Gray N, Zarrinkar P. 2008. High-throughput kinase profiling as a platform for drug discovery. Nat Rev Drug Disc 7:391-397.
51. Gong B, Vitolo OV, Trinchese F, Liu S, Shelanski M, Arancio O. 2004. Persistent improvement in synaptic and cognitive functions in an Alzheimer mouse model after rolipram treatment. J Clin Invest 114:1624-1634.
52. Goold RG, Gordon-Weeks PR. 2001. Microtubule-associated protein 1B phosphorylation by glycogen synthase kinase 3beta is induced during PC12 cell differentiation. J Cell Sci 114(Pt 23):4273-4284.
53. Goold RG, Owen R, Gordon-Weeks PR. 1999. Glycogen synthase kinase 3beta phosphorylation of microtubule-associated protein 1B regulates the stability of microtubules in growth cones. J Cell Sci 112(Pt 19):3373-3384.
54. Gould TD, Manji HK. 2005. Glycogen synthase kinase-3: a putative molecular target for lithium mimetic drugs. Neuropsychophar-macology 30:1223-1237.
55. Gupta S, Barrett T, Whitmarsh AJ, Cavanagh J, Sluss HK, Derijard B, Davis RJ. 1996. Selective interaction of JNK protein kinase isoforms with transcription factors. EMBO J 15:2760-2770.
56. Gustke N, Trinczek B, Biernat J, Mandelkow EM, Mandelkow E. 1994. Domains of tau protein and interactions with microtubules. Biochemistry 33:9511-9522.
57. Hall AC, Lucas FR, Salinas PC. 2000. Axonal remodeling and synaptic differentiation in the cerebellum is regulated by WNT-7a signaling. Cell 100:525-535.
58. Hallows JL, Chen K, DePinho RA, Vincent I. 2003. Decreased cyclin-dependent kinase 5 (cdk5) activity is accompanied by redistribution of cdk5 and cytoskeletal proteins and increased cytoskeletal protein phosphorylation in p35 null mice. J Neurosci 23:10633-10644.
59. Hanger DP, Byers HL, Wray S, Leung KY, Saxton MJ, Seereeram A, Reynolds CH, Ward MA, Anderton BH. 2007. Novel phosphorylation sites in tau from Alzheimer brain support a role for casein kinase 1 in disease pathogenesis. J Biol Chem 282:23645-23654.
60. Hayashi ML, Choi SY, Rao BS, Jung HY, Lee HK, Zhang D, Chattarji S, Kirkwood A, Tonegawa S. 2004. Altered cortical synaptic morphology and impaired memory consolidation in forebrain- specific dominant-negative PAK transgenic mice. Neuron 42:773-787.
61. Hensley K, Floyd RA, Zheng NY, Nael R, Robinson KA, Nguyen X, Pye QN, Stewart CA, Geddes J, Markesbery WR, Patel E, Johnson GV, Bing G. 1999. p38 kinase is activated in the Alzheimer's disease brain. J Neurochem 72:2053-2058.
62. Hernandez F, Borrell J, Guaza C, Avila J, Lucas JJ. 2002. Spatial learning deficit in transgenic mice that conditionally over-express GSK-3beta in the brain but do not form tau filaments. J Neurochem 83:1529-1533.
63. Hoeflich KP, Luo J, Rubie EA, Tsao MS, Jin O, Woodgett JR. 2000. Requirement for glycogen synthase kinase-3beta in cell survival and NF-kappaB activation. Nature 406:86-90.
64. Holmes C, Boche D, Wilkinson D, Yadegarfar G, Hopkins V, Bayer A, Jones RW, Bullock R, Love S, Neal JW, Zotova E, Nicoll JA. 2008. Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet 372:216-223.
65. Hong M, Chen DC, Klein PS, Lee VM. 1997. Lithium reduces tau phosphorylation by inhibition of glycogen synthase kinase-3. J Biol Chem 272:25326-25332.
66. Hooper C, Killick R, Lovestone S. 2008. The GSK3 hypothesis of Alzheimer's disease. J Neurochem 104:1433-1439.
67. Hutton M. 2001. Missense and splice site mutations in tau associated with FTDP-17: multiple pathogenic mechanisms. Neurology 56(Suppl 4):S21-S25.
68. Hwang DY, Cho JS, Lee SH, Chae KR, Lim HJ, Min SH, Seo SJ, Song YS, Song CW, Paik SG, Sheen YY, Kim YK. 2004. Aberrant expressions of pathogenic phenotype in Alzheimer's diseased transgenic mice carrying NSE-controlled APPsw. Exp Neurol 186:20-32.
69. Hyman BT, Augustinack JC, Ingelsson M. 2005. Transcriptional and conformational changes of the tau molecule in Alzheimer's disease. Biochim Biophys Acta 1739:150-157.
70. Iqbal K, Grundke-Iqbal I. 1996. Molecular mechanism of Alzheimer's neurofibrillary degeneration and therapeutic intervention. Ann NY Acad Sci 777:132-138.
71. Iqbal K, Grundke-Iqbal I. 2006. Discoveries of tau, abnormally hyperphosphorylated tau, et al of neurofibrillary degeneration: a personal historical perspective. J Alzheimers Dis 9(Suppl):219-242.
72. Iqbal K, Alonso Adel C, Grundke-Iqbal I. 2008. Cytosolic abnormally hyperphosphorylated tau but not paired helical filaments sequester normal MAPs and inhibit microtubule assembly. J Alzheimers Dis 14:365-370.
73. Ishihara T, Hong M, Zhang B, Nakagawa Y, Lee MK, Trojanowski JQ, Lee VM. 1999. Age-dependent emergence and progression of a tauopathy in transgenic mice overexpressing the shortest human tau isoform. Neuron 24:751-762.
74. Jackson GR, Wiedau-Pazos M, Sang TK, Wagle N, Brown CA, Massachi S, Geschwind DH. 2002. Human wild-type tau interacts with wingless pathway components and produces neurofibrillary pathology in Drosophila. Neuron 34:509-519.
75. Jenkins SM, Zinnerman M, Garner C, Johnson GV. 2000. Modulation of tau phosphorylation and intracellular localization by cellular stress. Biochem J 345(Pt 2):263-270.
76. Karaman MW, Herrgard S, Treiber DK, Gallant P, Atteridge CE, Campbell BT, Chan KW, Ciceri P, Davis MI, Edeen PT, Faraoni R, Floyd M, Hunt JP, Lockhart DJ, Milanov ZV, Morrison MJ, Pallares G, Patel HK, Pritchard S, Wodicka LM, Zarrinkar PP. 2008. A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol 26:127-132.
77. Karran E, Palmer AM. 2007. Neurodegenerative disorders and their treatment. Drug News Perspect 20:407-412.
78. Kimura R, Kamino K, Yamamoto M, Nuripa A, Kida T, Kazui H, Hashimoto R, Tanaka T, Kudo T, Yamagata H, Tabara Y, Miki T, Akatsu H, Kosaka K, Funakoshi E, Nishitomi K, Sakaguchi G, Kato A, Hattori H, Uema T, Takeda M. 2007. The DYRK1A gene, encoded in chromosome 21 Down syndrome critical region, bridges between beta-amyloid production and tau phosphoryla- tion in Alzheimer disease. Hum Mol Genet 16:15-23.
79. Kishi M, Pan YA, Crump JG, Sanes JR. 2005. Mammalian SAD kinases are required for neuronal polarization. Science 307:929-932.
80. Kitazawa M, Oddo S, Yamasaki TR, Green KN, LaFerla FM. 2005. Lipopolysaccharide-induced inflammation exacerbates tau pathology by a cyclin-dependent kinase 5-mediated pathway in a transgenic model of Alzheimer's disease. J Neurosci 25:8843-8853.
81. Knippschild U, Gocht A, Wolff S, Huber N, Lohler J, Stoter M. 2005. The casein kinase 1 family: participation in multiple cellular processes in eukaryotes. Cell Signal 17:675-689.
82. Koyanagi M, Takahashi J, Arakawa Y, Doi D, Fukuda H, Hayashi H, Narumiya S, Hashimoto N. 2008. Inhibition of the Rho/ROCK pathway reduces apoptosis during transplantation of embryonic stem cell-derived neural precursors. J Neurosci Res 86:270-280.
83. Kunick C, Lauenroth K, Leost M, Meijer L, Lemcke T. 2004. 1-Azakenpaullone is a selective inhibitor of glycogen synthase kinase-3 beta. Bioorg Med Chem Lett 14:413-416.
84. Kuret J, Johnson GS, Cha D, Christenson ER, DeMaggio AJ, Hoekstra MF. 1997. Casein kinase 1 is tightly associated with paired-helical filaments isolated from Alzheimer's disease brain. J Neurochem 69:2506-2515.
85. Lau KF, Howlett DR, Kesavapany S, Standen CL, Dingwall C, McLoughlin DM, Miller CC. 2002. Cyclin-dependent kinase-5/p35 phosphorylates Presenilin 1 to regulate carboxy-terminal fragment stability. Mol Cell Neurosci 20:13-20.
86. Lau KF, Miller CC, Anderton BH, Shaw PC. 1999. Expression analysis of glycogen synthase kinase-3 in human tissues. J Pept Res 54:85-91.
87. Leclerc S, Garnier M, Hoessel R, Marko D, Bibb JA, Snyder GL, Greengard P, Biernat J, Wu YZ, Mandelkow EM, Landvatter SW, Eisenbrand G, Meijer L. 2001. Indirubins inhibit glycogen synthase kinase-3 beta and CDK5/p25, two protein kinases involved in abnormal tau phosphorylation in Alzheimer's disease. A property common to most cyclin-dependent kinase inhibitors? J Biol Chem 276:251-260.
88. Lee VM, Trojanowski JQ. 2001. Transgenic mouse models of tauopathies: prospects for animal models of Pick's disease. Neurology 56(Suppl 4):S26-30.
89. Lee VM, Trojanowski JQ. 2006. Progress from Alzheimer's tangles to pathological tau points towards more effective therapies now. J Alzheimers Dis 9(Suppl):257-262.
90. Lee JC, Laydon JT, McDonnell PC, Gallagher TF, Kumar S, Green D, McNulty D, Blumenthal MJ, Heys JR, Landvatter SW, Strickler JE, McLaughlin MM, Siemens IR, Fisher SM, Livi GP, White JR, Adams JL, Young PR. 1994. A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature 372:739-746.
91. Lee KY, Clark AW, Rosales JL, Chapman K, Fung T, Johnston RN. 1999. Elevated neuronal Cdc2-like kinase activity in the Alzheimer disease brain. Neurosci Res 34:21-29.
92. Lee MS, Kwon YT, Li M, Peng J, Friedlander RM, Tsai LH. 2000. Neurotoxicity induces cleavage of p35 to p25 by calpain. Nature 405:360-364.
93. Leroy K, Brion JP. 1999. Developmental expression and localization of glycogen synthase kinase-3beta in rat brain. J Chem Neuroanat 16:279-293.
94. Li G, Yin H, Kuret J. 2004. Casein kinase 1 delta phosphorylates tau and disrupts its binding to microtubules. J Biol Chem 279:15938-15945.
95. Li T, Paudel HK. 2006. Glycogen synthase kinase 3beta phosphor- ylates Alzheimer's disease-specific Ser396 of microtubule-asso-ciated protein tau by a sequential mechanism. Biochemistry 45:3125-3133.
96. Li T, Hawkes C, Qureshi HY, Kar S, Paudel HK. 2006. Cyclin-dependent protein kinase 5 primes microtubule-associated protein tau site-specifically for glycogen synthase kinase 3beta. Biochemistry 45:3134-3145.
97. Liao JJ, Andrews RC. 2007. Targeting protein multiple conformations: a structure-based strategy for kinase drug design. Curr Top Med Chem 7:1394-1407.
98. Liou YC, Sun A, Ryo A, Zhou XZ, Yu ZX, Huang HK, Uchida T, Bronson R, Bing G, Li X, Hunter T, Lu KP. 2003. Role of the prolyl isomerase Pin1 in protecting against age-dependent neurodegeneration. Nature 424:556-561.
99. Lisman J, Schulman H, Cline H. 2002. The molecular basis of CaMKII function in synaptic and behavioural memory. Nat Rev Neurosci 3:175-190.
100. Litersky JM, Johnson GV, Jakes R, Goedert M, Lee M, Seubert P. 1996. Tau protein is phosphorylated by cyclic AMP-dependent protein kinase and calcium/calmodulin-dependent protein kinase II within its microtubule-binding domains at Ser-262 and Ser-356. Biochem J 316(Pt 2):655-660.
101. Liu F, Su Y, Li B, Zhou Y, Ryder J, Gonzalez-DeWhitt P, May PC, Ni B. 2003. Regulation of amyloid precursor protein (APP) phosphorylation and processing by p35/Cdk5 and p25/Cdk5. FEBS Lett 547:193-196.
102. Lovestone S, Davis DR, Webster MT, Kaech S, Brion JP, Matus A, Anderton BH. 1999. Lithium reduces tau phosphorylation: effects in living cells and in neurons at therapeutic concentrations. Biol Psychiatry 45:995-1003.
103. Lovestone S, Hartley CL, Pearce J, Anderton BH. 1996. Phosphor- ylation of tau by glycogen synthase kinase-3 beta in intact mammalian cells: the effects on the organization and stability of microtubules. Neuroscience 73:1145-1157.
104. Lucas FR, Salinas PC. 1997. WNT-7a induces axonal remodeling and increases synapsin I levels in cerebellar neurons. Dev Biol 192:31-44.
105. Lucas JJ, Hernandez F, Gomez-Ramos P, Moran MA, Hen R, Avila J. 2001. Decreased nuclear beta-catenin, tau hyperpho- sphorylation and neurodegeneration in GSK-3beta conditional transgenic mice. EMBO J 20:27-39.
106. Mandelkow EM, Stamer K, Vogel R, Thies E, Mandelkow E. 2003. Clogging of axons by tau, inhibition of axonal traffic and starvation of synapses. Neurobiol Aging 24:1079-1085.
107. Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S. 2002. The protein kinase complement of the human genome. Science 298:1912-1934.
108. Mapelli M, Massimiliano L, Crovace C, Seeliger MA, Tsai LH, Meijer L, Musacchio A. 2005. Mechanism of CDK5/p25 binding by CDK inhibitors. J Med Chem 48:671-679.
109. Maritzen T, Lohler J, Deppert W, Knippschild U. 2003. Casein kinase I delta (CKIdelta) is involved in lymphocyte physiology. Eur J Cell Biol 82:369-378.
110. Maroney AC, Finn JP, Connors TJ, Durkin JT, Angeles T, Gessner G, Xu Z, Meyer SL, Savage MJ, Greene LA, Scott RW, Vaught JL. 2001. Cep-1347 (KT7515), a semisynthetic inhibitor of the mixed lineage kinase family. J Biol Chem 276:25302-25308.
111. Mazanetz MP, Fischer PM. 2007. Untangling tau hyperphosphor- ylation in drug design for neurodegenerative diseases. Nat Rev Drug Discov 6:464-479.
112. McCaffrey P, Strobel G. 2007. European trial of Alzhemed ends, marketing morphs to supplement. Alz Res Forum http://www.alzforum.org/new/detail.asp?id = 1691.
113. McDonald DR, Bamberger ME, Combs CK, Landreth GE. 1998. beta-Amyloid fibrils activate parallel mitogen-activated protein kinase pathways in microglia and THP1 monocytes. J Neurosci 18:4451-4460.
114. McKerracher L, Higuchi H. 2006. Targeting Rho to stimulate repair after spinal cord injury. J Neurotrauma 23:309-317.
115. Meijer L, Flajolet M, Greengard P. 2004. Pharmacological inhibitors of glycogen synthase kinase 3. Trends Pharmacol Sci 25:471-480.
116. Meijer L, Thunnissen AM, White AW, Garnier M, Nikolic M, Tsai LH, Walter J, Cleverley KE, Salinas PC, Wu YZ, Biernat J, Mandelkow EM, Kim SH, Pettit GR. 2000. Inhibition of cyclin-dependent kinases, GSK-3beta and CK1 by hymenialdisine, a marine sponge constituent. Chem Biol 7:51-63.
117. Mettey Y, Gompel M, Thomas V, Garnier M, Leost M, Ceballos-Picot I, Noble M, Endicott J, Vierfond JM, Meijer L. 2003. Aloisines, a new family of CDK/GSK-3 inhibitors. SAR study, crystal structure in complex with CDK2, enzyme selectivity, and cellular effects. J Med Chem 46:222-236.
118. Milton NG. 2001. Phosphorylation of amyloid-beta at the serine 26 residue by human cdc2 kinase. NeuroReport 12:3839-3844.
119. Morishima Y, Gotoh Y, Zieg J, Barrett T, Takano H, Flavell R, Davis RJ, Shirasaki Y, Greenberg ME. 2001. Beta-amyloid induces neuronal apoptosis via a mechanism that involves the c-Jun N-terminal kinase pathway and the induction of Fas ligand. J Neurosci 21:7551-7560.
120. Mudher A, Shepherd D, Newman TA, Mildren P, Jukes JP, Squire A, Mears A, Drummond JA, Berg S, MacKay D, Asuni AA, Bhat R, Lovestone S. 2004. GSK-3beta inhibition reverses axonal transport defects and behavioural phenotypes in Drosophila. Mol Psychiatry 9:522-530.
121. Mudher AK, Perry VH. 1998. Using okadaic acid as a tool for the in vivo induction of hyperphosphorylated tau. Neuroscience 85:1329-1332.
122. Munoz L, Ranaivo HR, Roy SM, Hu W, Craft JM, McNamara LK, Chico LW, Van Eldik LJ, Watterson DM. 2007. A novel p38 alpha MAPK inhibitor suppresses brain proinflammatory cytokine up- regulation and attenuates synaptic dysfunction and behavioral deficits in an Alzheimer's disease mouse model. J Neuroinflam- mation 4:21.
123. Munoz-Montano JR, Lim F, Moreno FJ, Avila J, Diaz-Nido J. 1999. Glycogen synthase kinase-3 modulates neurite outgrowth in cultured neurons: possible implications for neurite pathology in Alzheimer's disease. J Alzheimers Dis 1:361-378.
124. Namgung U, Choi BH, Park S, Lee JU, Seo HS, Suh BC, Kim KT. 2004. Activation of cyclin-dependent kinase 5 is involved in axonal regeneration. Mol Cell Neurosci 25:422-432.
125. Necula M, Kuret J. 2004. Pseudophosphorylation and glycation of tau protein enhance but do not trigger fibrillization in vitro. J Biol Chem 279:49694-49703.
126. Neve RL, McPhie DL. 2006. The cell cycle as a therapeutic target for Alzheimer's disease. Pharmacol Ther 111:99-113.
127. Nguyen MD, Lariviere RC, Julien JP. 2001. Deregulation of Cdk5 in a mouse model of ALS: toxicity alleviated by perikaryal neurofilament inclusions. Neuron 30:135-147.
128. Nguyen TV, Galvan V, Huang W, Banwait S, Tang H, Zhang J, Bredesen DE. 2008. Signal transduction in Alzheimer disease: p21-activated kinase signaling requires C-terminal cleavage of APP at Asp664. J Neurochem 104:1065-1080.
129. Niederöst B, Oertle T, Fritsche J, McKinney RA, Bandtlow CE. 2002. Nogo-A and myelin-associated glycoprotein mediate neurite growth inhibition by antagonistic regulation of RhoA and Rac1. J Neurosci 22:10368-10376.
130. Nikolic M, Chou MM, Lu W, Mayer BJ, Tsai LH. 1998. The p35/Cdk5 kinase is a neuron-specific Rac effector that inhibits Pak1 activity. Nature 395:194-198.
131. Nikolic M, Dudek H, Kwon YT, Ramos YF, Tsai LH. 1996. The cdk5/p35 kinase is essential for neurite outgrowth during neuronal differentiation. Genes Dev 10:816-825.
132. Nishimura I, Yang Y, Lu B. 2004. PAR-1 kinase plays an initiator role in a temporally ordered phosphorylation process that confers tau toxicity in Drosophila. Cell 116:671-682.
133. Noble W, Olm V, Takata K, Casey E, Mary O, Meyerson J, Gaynor K, LaFrancois J, Wang L, Kondo T, Davies P, Burns M, Veeranna, Nixon R, Dickson D, Matsuoka Y, Ahlijanian M, Lau LF, Duff K. 2003. Cdk5 is a key factor in tau aggregation and tangle formation in vivo. Neuron 38:555-565.
134. Ohshima T, Ward JM, Huh CG, Longenecker G, Veeranna, Pant HC, Brady RO, Martin LJ, Kulkarni AB. 1996. Targeted disruption of the cyclin-dependent kinase 5 gene results in abnormal corticogenesis, neuronal pathology and perinatal death. Proc Natl Acad Sci USA 93:11173-11178.
135. Okamura A, Iwata N, Nagata A, Tamekane A, Shimoyama M, Gomyo H, Yakushijin K, Urahama N, Hamaguchi M, Fukui C, Chihara K, Ito M, Matsui T. 2004. Involvement of casein kinase Iepsilon in cytokine-induced granulocytic differentiation. Blood 103:2997-3004.
136. Olsen M. 2008. Applications for ROCK kinase inhibition. Curr Opin Cell Biol. 20:242-248.
137. Owen R, Gordon-Weeks PR. 2003. Inhibition of glycogen synthase kinase 3beta in sensory neurons in culture alters filopodia dynamics and microtubule distribution in growth cones. Mol Cell Neurosci 23:626-637.
138. Pardridge WM. 2007. Drug targeting to the brain. Pharm Res 24:1733-1744.
139. Pargellis C, Tong L, Churchill L, Cirillo PF, Gilmore T, Graham AG, Grob PM, Hickey ER, Moss N, Pav S, Regan J. 2002. Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site. Nat Struct Biol 9:268-272.
140. Parkinson Study Group PRECEPT Investigators. 2007. Mixed lineage kinase inhibitor CEP-1347 fails to delay disability in early Parkinson disease. Neurology 69:1480-1490.
141. Patrick GN, Zukerberg L, Nikolic M, de la Monte S, Dikkes P, Tsai LH. 1999. Conversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration. Nature 402:615-622.
142. Paudel HK. 1997. Phosphorylation by neuronal cdc2-like protein kinase promotes dimerization of Tau protein in vitro. J Biol Chem 272:28328-28334.
143. Pearson G, Robinson F, Beers Gibson T, Xu BE, Karandikar M, Berman K, Cobb MH. 2001. Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions. Endocr Rev 22:153-183.
144. Pei JJ, Tanaka T, Tung YC, Braak E, Iqbal K, Grundke-Iqbal I. 1997. Distribution, levels, and activity of glycogen synthase kinase-3 in the Alzheimer disease brain. J Neuropathol Exp Neurol 56:70-78.
145. Perez M, Hernandez F, Lim F, Diaz-Nido J, Avila J. 2003. Chronic lithium treatment decreases mutant tau protein aggregation in a transgenic mouse model. J Alzheimers Dis 5:301-308.
146. Perry G, Roder H, Nunomura A, Takeda A, Friedlich AL, Zhu X, Raina AK, Holbrook N, Siedlak SL, Harris PL, Smith MA. 1999. Activation of neuronal extracellular receptor kinase (ERK) in Alzheimer disease links oxidative stress to abnormal phosphoryla- tion. NeuroReport 10:2411-2415.
147. Petratos S, Li QX, George AJ, Hou X, Kerr ML, Unabia SE, Hatzinisiriou I, Maksel D, Aguilar MI, Small DH. 2008. The beta-amyloid protein of Alzheimer's disease increases neuronal CRMP- 2 phosphorylation by a Rho-GTP mechanism. Brain 131(Pt 1):90-108.
148. Phiel CJ, Wilson CA, Lee VM, Klein PS. 2003. GSK-3alpha regulates production of Alzheimer's disease amyloid-beta pep-tides. Nature 423:435-439.
149. Philpott KL, Facci L. 2008. MAP kinase pathways in neuronal cell death. CNS Neurol Disord Drug Targets 7:83-97.
150. Pickhardt M, Gazova Z, von Bergen M, Khlistunova I, Wang Y, Hascher A, Mandelkow EM, Biernat J, Mandelkow E. 2005. Anthraquinones inhibit tau aggregation and dissolve Alzheimer's paired helical filaments in vitro and in cells. J Biol Chem 280:3628-3635.
151. Plattner F, Angelo M, Giese KP. 2006. The roles ofcyclin-dependent kinase 5 and glycogen synthase kinase 3 in tau hyperpho-sphorylation. J Biol Chem 281:25457-25465.
152. Preuss U, Biernat J, Mandelkow EM, Mandelkow E. 1997. The 'jaws' model of tau-microtubule interaction examined in CHO cells. J Cell Sci 110(Pt 6):789-800.
153. Probst A, Gotz J, Wiederhold KH, Tolnay M, Mistl C, Jaton AL, Hong M, Ishihara T, Lee VM, Trojanowski JQ, Jakes R, Crowther RA, Spillantini MG, Burki K, Goedert M. 2000. Axonopathy and amyotrophy in mice transgenic for human four- repeat tau protein. Acta Neuropathol 99:469-481.
154. Pyo H, Jou I, Jung S, Hong S, Joe EH. 1998. Mitogen-activated protein kinases activated by lipopolysaccharide and beta-amyloid in cultured rat microglia. NeuroReport 9:871-874.
155. Qin W, Yang T, Ho L, Zhao Z, Wang J, Chen L, Zhao W, Thiyagarajan M, MacGrogan D, Rodgers JT, Puigserver P, Sadoshima J, Deng H, Pedrini S, Gandy S, Sauve AA, Pasinetti GM. 2006. Neuronal SIRT1 activation as a novel mechanism underlying the prevention of Alzheimer disease amyloid neuropathology by calorie restriction. J Biol Chem 281:21745-21754.
156. Reynolds CH, Betts JC, Blackstock WP, Nebreda AR, Anderton BH. 2000. Phosphorylation sites on tau identified by nanoelectrospray mass spectrometry: differences in vitro between the mitogen- activated protein kinases ERK2, c-Jun N-terminal kinase and P38, and glycogen synthase kinase-3beta. J Neurochem 74:1587-1595.
157. Ridley A. 2006. Rho GTPases and actin dynamics in membrane protrusions and vesicle trafficking. Trends in Cell Biology 16:522-529.
158. Rojo LE, Fernandez JA, Maccioni AA, Jimenez JM, Maccioni RB. 2008. Neuroinflammation: implications for the pathogenesis and molecular diagnosis of Alzheimer's disease. Arch Med Res 39:1-16.
159. Ross JL, Santangelo CD, Makrides V, Fygenson DK. 2004. Tau induces cooperative Taxol binding to microtubules. Proc Natl Acad Sci USA 101:12910-12915.
160. Ryder J, Su Y, Liu F, Li B, Zhou Y, Ni B. 2003. Divergent roles of GSK3 and CDK5 in APP processing. Biochem Biophys Res Commun 312:922-929.
161. Ryoo SR, Jeong HK, Radnaabazar C, Yoo JJ, Cho HJ, Lee HW, Kim IS, Cheon YH, Ahn YS, Chung SH, Song WJ. 2007. DYRK1A-mediated hyperphosphorylation of Tau. A functional link between Down syndrome and Alzheimer disease. J Biol Chem 282:34850-34857.
162. Ryoo SR, Cho HJ, Lee HW, Jeong HK, Radnaabazar C, Kim YS, Kim MJ, Son MY, Seo H, Chung SH, Song WJ. 2008. Dual-specificity tyrosine(Y)-phosphorylation regulated kinase 1A-mediated phosphorylation of amyloid precursor protein: evidence for a functional link between Down syndrome and Alzheimer's disease. J Neurochem 104:1333-1344.
163. Sahara N, Lewis J, DeTure M, McGowan E, Dickson DW, Hutton M, Yen SH. 2002. Assembly of tau in transgenic animals expressing P301L tau: alteration of phosphorylation and solubility. J Neurochem 83:1498-1508
164. Sahara N, Murayama M, Lee B, Park JM, Lagalwar S, Binder LI, Takashima A. 2008. Active c-jun N-terminal kinase induces caspase cleavage of tau and additional phosphorylation by GSK- 3beta is required for tau aggregation. Eur J Neurosci 27:2897-2906.
165. Santacruz K, Lewis J, Spires T, Paulson J, Kotilinek L, Ingelsson M, Guimaraes A, DeTure M, Ramsden M, McGowan E, Forster C, Yue M, Orne J, Janus C, Mariash A, Kuskowski M, Hyman B, Hutton M, Ashe KH. 2005. Tau suppression in a neurodegenerative mouse model improves memory function. Science 309:476-481.
166. Sarno S, Ruzzene M, Frascella P, Pagano MA, Meggio F, Zambon A, Mazzorana M, Di Maira G, Lucchini V, Pinna LA. 2005. Development and exploitation of CK2 inhibitors. Mol Cell Biochem 274:69-76.
167. Saura CA, Choi SY, Beglopoulos V, Malkani S, Zhang D, Shankaranarayana Rao BS, Chattarji S, Kelleher RJ, Kandel 3rd ER, Duff K, Kirkwood A, Shen J. 2004. Loss of presenilin function causes impairments of memory and synaptic plasticity followed by age-dependent neurodegeneration. Neuron 42:23-36.
168. Savage MJ, Lin YG, Ciallella JR, Flood DG, Scott RW. 2002. Activation of c-Jun N-terminal kinase and p38 in an Alzheimer's disease model is associated with amyloid deposition. J Neurosci 22:3376-3385.
169. Selkoe DJ. 1991. The molecular pathology of Alzheimer's disease. Neuron 6:487-498.
170. Sengupta A, Wu Q, Grundke-Iqbal I, Iqbal K, Singh TJ. 1997. Potentiation of GSK-3-catalyzed Alzheimer-like phosphorylation of human tau by cdk5. Mol Cell Biochem 167:99-105.
171. Shaftel SS, Griffin WS, O'Banion MK. 2008. The role of interleukin-1 in neuroinflammation and Alzheimer disease: an evolving perspective. J Neuroinflammation 5:7.
172. Shen C, Chen Y, Liu H, Zhang K, Zhang T, Lin A, Jing N. 2008. Hydrogen peroxide promotes Abeta production through JNK- dependent activation of gamma-secretase. J Biol Chem 283:17721-17730.
173. Shen L, Prouty C, Conway BR, Westover L, Xu JZ, Look RA, Chen X, Beavers MP, Roberts J, Murray WV, Demarest KT, Kuo GH. 2004. Synthesis and biological evaluation of novel macrocyclic bis-7-azaindolylmaleimides as potent and highly selective glycogen synthase kinase-3 beta (GSK-3 beta) inhibitors. Bioorg Med Chem 12:1239-1255.
174. Shoji M, Iwakami N, Takeuchi S, Waragai M, Suzuki M, Kanazawa I, Lippa CF, Ono S, Okazawa H. 2000. JNK activation is associated with intracellular beta-amyloid accumulation. Brain Res Mol Brain Res 85:221-233.
175. Sironi JJ, Yen SH, Gondal JA, Wu Q, Grundke-Iqbal I, Iqbal K. 1998. Ser-262 in human recombinant tau protein is a markedly more favorable site for phosphorylation by CaMKII than PKA or PhK. FEBS Lett 436:471-475.
176. Sisodia SS, St George-Hyslop PH. 2002. gamma-Secretase, Notch, Abeta and Alzheimer's disease: where do the presenilins fit in? Nat Rev Neurosci 3:281-290.
177. Skovronsky DM, Lee VM, Trojanowski JQ. 2006. Neurodegenera- tive diseases: new concepts of pathogenesis and their therapeutic implications. Annu Rev Pathol 1:151-170.
178. Sorbera LA, Bozzo J, Serradell N. 2007 Alzheimer's disease one century later: the search for effective therapeutic targets continues. Drugs Future 32: 625-641.
179. Sperber BR, Leight S, Goedert M, Lee VM. 1995. Glycogen synthase kinase-3 beta phosphorylates tau protein at multiple sites in intact cells. Neurosci Lett 197:149-153.
180. Spittaels K, Van den Haute C, Van Dorpe J, Bruynseels K, Vandezande K, Laenen I, Geerts H, Mercken M, Sciot R, Van Lommel A, Loos R, Van Leuven F. 1999. Prominent axonopathy in the brain and spinal cord of transgenic mice overexpressing four-repeat human tau protein. Am J Pathol 155:2153-2165.
181. Stokin GB, Lillo C, Falzone TL, Brusch RG, Rockenstein E, Mount SL, Raman R, Davies P, Masliah E, Williams DS, Goldstein LS. 2005. Axonopathy and transport deficits early in the pathogenesis of Alzheimer's disease. Science 307:1282-1288.
182. Strobel G. 2008. Bapineuzumab's Phase 2-was the data better than the spin? Alz Res Forum http://www.alzforum.org/new/detail.asp?id = 1894.
183. Sugden PH, Fuller SJ, Weiss SC, Clerk A. 2008. Glycogen synthase kinase 3 (GSK3) in the heart: a point of integration in hypertrophic signalling and a therapeutic target? A critical analysis. Br J Pharmacol. 153(Suppl 1):S137-S153.
184. Sun W, Qureshi HY, Cafferty PW, Sobue K, Agarwal-Mawal A, Neufield KD, Paudel HK. 2002a. Glycogen synthase kinase-3beta is complexed with tau protein in brain microtubules. J Biol Chem 277:11933-11940.
185. Sun X, Sato S, Murayama O, Murayama M, Park JM, Yamaguchi H, Takashima A. 2002b. Lithium inhibits amyloid secretion in COS7 cells transfected with amyloid precursor protein C100. Neurosci Lett 321:61-64.
186. Takashima A, Noguchi K, Michel G, Mercken M, Hoshi M, Ishiguro K, Imahori K. 1996. Exposure of rat hippocampal neurons to amyloid beta peptide (25-35) induces the inactivation of phosphatidyl inositol-3 kinase and the activation of tau protein kinase I/glycogen synthase kinase-3 beta. Neurosci Lett 203:33-36.
187. Takashima A, Honda T, Yasutake K, Michel G, Murayama O, Murayama M, Ishiguro K, Yamaguchi H. 1998. Activation of tau protein kinase I/glycogen synthase kinase-3beta by amyloid beta peptide (25-35) enhances phosphorylation of tau in hippocampal neurons. Neurosci Res 31:317-323.
188. Terry RD. 1996. The pathogenesis of Alzheimer disease: an alternative to the amyloid hypothesis. J Neuropathol Exp Neurol 55:1023-1025.
189. Tesco G, Tanzi RE. 2000. GSK3 beta forms a tetrameric complex with endogenous PS1-CTF/NTF and beta-catenin. Effects of the D257/D385A and FAD-linked mutations. Ann N Y Acad Sci 920:227-232.
190. Thakur A, Wang X, Siedlak SL, Perry G, Smith MA, Zhu X. 2007. c-Jun phosphorylation in Alzheimer disease. J Neurosci Res 85:1668-1673.
191. Tian Q, Wang J. 2002. Role of serine/threonine protein phosphatase in Alzheimer's disease. Neurosignals 11:262-269.
192. Tomizawa K, Ohta J, Matsushita M, Moriwaki A, Li ST, Takei K, Matsui H. 2002. Cdk5/p35 regulates neurotransmitter release through phosphorylation and downregulation of P/Q-type voltage- dependent calcium channel activity. J Neurosci 22:2590-2597.
193. Trojanowski JQ, Smith AB, Huryn D, Lee VM. 2005. Microtubule-stabilising drugs for therapy of Alzheimer's disease and other neurodegenerative disorders with axonal transport impairments. Expert Opin Pharmacother 6:683-686.
194. Troy CM, Rabacchi SA, Xu Z, Maroney AC, Connors TJ, Shelanski ML, Greene LA. 2001. beta-Amyloid-induced neuronal apoptosis requires c-Jun N-terminal kinase activation. J Neuro-chem 77:157-164.
195. Tsai LH. 2006. The effect of CDK inhibitors in a mouse model for Alzheimer's disease. http://www.pasteur.fr/applications/euroconf/proteinkinase/ 10Tsaiabstract.pdf.
196. Tsai LH, Delalle I, Caviness Jr VS, Chae T, Harlow E. 1994. p35 is a neural-specific regulatory subunit of cyclin-dependent kinase 5. Nature 371:419-423.
197. Vetrivel KS, Thinakaran G. 2006. Amyloidogenic processing of beta-amyloid precursor protein in intracellular compartments. Neurology 66(Suppl 1):S69-S73.
198. Vogelsberg-Ragaglia V, Schuck T, Trojanowski JQ, Lee VM. 2001. PP2A mRNA expression is quantitatively decreased in Alzheimer's disease hippocampus. Exp Neurol 168:402-412.
199. Wagner U, Utton M, Gallo JM, Miller CC. 1996. Cellular phosphorylation of tau by GSK-3 beta influences tau binding to microtubules and microtubule organisation. J Cell Sci 109(Pt 6):1537-1543.
200. Waldmeier P, Bozyczko-Coyne D, Williams M, Vaught JL. 2006. Recent clinical failures in Parkinson's disease with apoptosis inhibitors underline the need for a paradigm shift in drug discovery for neurodegenerative diseases. Biochem Pharmacol 72:1197-1206.
201. Wan Y, Hur W, Cho CY, Liu Y, Adrian FJ, Lozach O, Bach S, Mayer T, Fabbro D, Meijer L, Gray NS. 2004. Synthesis and target identification of hymenialdisine analogs. Chem Biol 11:247-259.
202. Wang L, Shim H, Xie C, Cai H. 2008. Activation of protein kinase C modulates BACE1-mediated beta-secretase activity. Neurobiol Aging 29:357-367.
203. Wang Q, Walsh DM, Rowan MJ, Selkoe DJ, Anwyl R. 2004. Block of long-term potentiation by naturally secreted and synthetic amyloid beta-peptide in hippocampal slices is mediated via activation of the kinases c-Jun N-terminal kinase, cyclin- dependent kinase 5, and p38 mitogen-activated protein kinase as well as metabotropic glutamate receptor type 5. J Neurosci 24:3370-3378.
204. Welsh GI, Proud CG. 1993. Glycogen synthase kinase-3 is rapidly inactivated in response to insulin and phosphorylates eukaryotic initiation factor eIF-2B. Biochem J 294(Pt 3):625-629.
205. Wen Y, Planel E, Herman M, Figueroa HY, Wang L, Liu L, Lau LF, Yu WH, Duff KE. 2008. Interplay between cyclin-dependent kinase 5 and glycogen synthase kinase 3 beta mediated by neuregulin signaling leads to differential effects on tau phosphor- ylation and amyloid precursor protein processing. J Neurosci 28:2624-2632.
206. Wilcock GK, Black SE, Hendrix SB, Zavitz KH, Swabb EA, Laughlin MA; Tarenflurbil Phase II Study investigators. 2008. Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial. Lancet Neurol. 7:483-493.
207. Wischik CM, Edwards PC, Lai RY, Roth M, Harrington CR. 1996. Selective inhibition of Alzheimer disease-like tau aggregation by phenothiazines. Proc Natl Acad Sci USA 93:11213-11218.
208. Witherington J, Blaney EL, Bordas V, Elliott RL, Gaiba A, Garton N, Green PM, Naylor A, Smith DG, Spalding DJ, Takle AK, Ward RW. 2006. Pyridone derivatives as potent, orally bioavailable VLA-4 integrin antagonists. Bioorg Med Chem Lett 16:5538-5541.
209. Wittmann CW, Wszolek MF, Shulman JM, Salvaterra PM, Lewis J, Hutton M, Feany MB. 2001. Tauopathy in Drosophila: neurode- generation without neurofibrillary tangles. Science 293:711-714.
210. Woodgett JR. 1990. Molecular cloning and expression of glycogen synthase kinase-3/factor A. EMBO J 9:2431-2438.
211. Xiong W, Pestell R, Rosner MR. 1997. Role of cyclins in neuronal differentiation of immortalized hippocampal cells. Mol Cell Biol 17:6585-6597.
212. Yasojima K, Kuret J, DeMaggio AJ, McGeer E, McGeer PL. 2000. Casein kinase 1 delta mRNA is upregulated in Alzheimer disease brain. Brain Res 865:116-120.
213. Yuzwa SA, Macauley MS, Heinonen JE, Shan X, Dennis RJ, He Y, Whitworth GE, Stubbs KA, McEachern EJ, Davies GJ, Vocadlo DJ. 2008. A potent mechanism-inspired O-GlcNAcase inhibitor that blocks phosphorylation of tau in vivo. Nat Chem Biol 4:483-490.
214. Zhai S, Senderowicz AM, Sausville EA, Figg WD. 2002. Flavopir-idol, a novel cyclin-dependent kinase inhibitor, in clinical development. Ann Pharmacother 36:905-911.
215. Zhang B, Maiti A, Shively S, Lakhani F, McDonald-Jones G, Bruce J, Lee EB, Xie SX, Joyce S, Li C, Toleikis PM, Lee VM, Trojanowski JQ. 2005. Microtubule-binding drugs offset tau sequestration by stabilizing microtubules and reversing fast axonal transport deficits in a tauopathy model. Proc Natl Acad Sci USA 102:227-231.
216. Zhang M, Li J, Chakrabarty P, Bu B, Vincent I. 2004. Cyclin-dependent kinase inhibitors attenuate protein hyperphosphoryla- tion, cytoskeletal lesion formation, and motor defects in Niemann-Pick Type C mice. Am J Pathol 165:843-853.
217. Zhao L, Ma QL, Calon F, Harris-White ME, Yang F, Lim GP, Morihara T, Ubeda OJ, Ambegaokar S, Hansen JE, Weisbart RH, Teter B, Frautschy SA, Cole GM. 2006. Role of p21-activated kinase pathway defects in the cognitive deficits of Alzheimer disease. Nat Neurosci 9:234-242.
218. Zhou Y, Su Y, Li B, Liu F, Ryder JW, Wu X, Gonzalez-DeWhitt PA, Gelfanova V, Hale JE, May PC, Paul SM, Ni B. 2003. Nonsteroidal anti-inflammatory drugs can lower amyloidogenic Abeta42 by inhibiting Rho. Science 302:1215-1217.
219. Zhu X, Castellani RJ, Takeda A, Nunomura A, Atwood CS, Perry G, Smith MA. 2001a. Differential activation of neuronal ERK, JNK/SAPK and p38 in Alzheimer disease: the 'two hit' hypothesis. Mech Ageing Dev 123:39-46.
220. Zhu X, Raina AK, Rottkamp CA, Aliev G, Perry G, Boux H, Smith MA. 2001b. Activation and redistribution of c-jun N-terminal kinase/stress activated protein kinase in degenerating neurons in Alzheimer's disease. J Neurochem 76:435-441.
221. Zhu X, Rottkamp CA, Boux H, Takeda A, Perry G, Smith MA. 2000. Activation of p38 kinase links tau phosphorylation, oxidative stress, and cell cycle-related events in Alzheimer disease. J Neuropathol Exp Neurol 59:880-888.